235 related articles for article (PubMed ID: 27605597)
21. Hepatitis C virus genetic diversity by geographic region within genotype 1-6 subtypes among patients treated with glecaprevir and pibrentasvir.
Schnell G; Krishnan P; Tripathi R; Beyer J; Reisch T; Irvin M; Dekhtyar T; Lu L; Ng TI; Xie W; Pilot-Matias T; Collins C
PLoS One; 2018; 13(10):e0205186. PubMed ID: 30286205
[TBL] [Abstract][Full Text] [Related]
22. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection.
Sulkowski MS; Gardiner DF; Rodriguez-Torres M; Reddy KR; Hassanein T; Jacobson I; Lawitz E; Lok AS; Hinestrosa F; Thuluvath PJ; Schwartz H; Nelson DR; Everson GT; Eley T; Wind-Rotolo M; Huang SP; Gao M; Hernandez D; McPhee F; Sherman D; Hindes R; Symonds W; Pasquinelli C; Grasela DM;
N Engl J Med; 2014 Jan; 370(3):211-21. PubMed ID: 24428467
[TBL] [Abstract][Full Text] [Related]
23. Efficacy and safety of 12 weeks of daclatasvir, asunaprevir plus ribavirin for HCV genotype-1b infection without NS5A resistance-associated substitutions.
Yu ML; Hung CH; Huang YH; Peng CY; Lin CY; Cheng PN; Chien RN; Hsu SJ; Liu CH; Huang CF; Su CW; Huang JF; Liu CJ; Kao JH; Chuang WL; Chen PJ; Chen DS
J Formos Med Assoc; 2019 Feb; 118(2):556-564. PubMed ID: 30527566
[TBL] [Abstract][Full Text] [Related]
24. Addition of ribavirin to daclatasvir plus asunaprevir for chronic hepatitis C 1b patients with baseline NS5A resistance-associated variants improved response.
Hong CM; Liu CJ; Yeh SH; Chen PJ
J Formos Med Assoc; 2017 Apr; 116(4):295-299. PubMed ID: 28034492
[TBL] [Abstract][Full Text] [Related]
25. HCV phylogenetic signature and prevalence of pretreatment NS5A and NS5B NI-Resistance associated substitutions in HCV-Infected patients in Mainland China.
Wei L; Omata M; Lim YS; Xie Q; Hou JL; Jia J; Hedskog C; Martin R; Doehle B; Yang J; De-Oertel S; Massetto B; Kersey K; Brainard DM; Svarovskaia E; Mo H; Han KH; Mizokami M; Duan Z
Antiviral Res; 2018 Oct; 158():178-184. PubMed ID: 30120954
[TBL] [Abstract][Full Text] [Related]
26. Regulatory Analysis of Effects of Hepatitis C Virus NS5A Polymorphisms on Efficacy of Elbasvir and Grazoprevir.
Komatsu TE; Boyd S; Sherwat A; Tracy L; Naeger LK; O'Rear JJ; Harrington PR
Gastroenterology; 2017 Feb; 152(3):586-597. PubMed ID: 27773808
[TBL] [Abstract][Full Text] [Related]
27. Clinical Resistance to Velpatasvir (GS-5816), a Novel Pan-Genotypic Inhibitor of the Hepatitis C Virus NS5A Protein.
Lawitz EJ; Dvory-Sobol H; Doehle BP; Worth AS; McNally J; Brainard DM; Link JO; Miller MD; Mo H
Antimicrob Agents Chemother; 2016 Sep; 60(9):5368-78. PubMed ID: 27353271
[TBL] [Abstract][Full Text] [Related]
28. High efficacy of resistance-guided retreatment of HCV patients failing NS5A inhibitors in the real world.
Pérez AB; Chueca N; García-Deltoro M; Martínez-Sapiña AM; Lara-Pérez MM; García-Bujalance S; Aldámiz-Echevarría T; Vera-Méndez FJ; Pineda JA; Casado M; Pascasio JM; Salmerón J; Alados-Arboledas JC; Poyato A; Téllez F; Rivero-Juárez A; Merino D; Vivancos-Gallego MJ; Rosales-Zábal JM; García F;
J Hepatol; 2019 Nov; 71(5):876-888. PubMed ID: 31279901
[TBL] [Abstract][Full Text] [Related]
29. Resistance analysis of hepatitis C virus genotype 1 prior treatment null responders receiving daclatasvir and asunaprevir.
McPhee F; Hernandez D; Yu F; Ueland J; Monikowski A; Carifa A; Falk P; Wang C; Fridell R; Eley T; Zhou N; Gardiner D
Hepatology; 2013 Sep; 58(3):902-11. PubMed ID: 23504694
[TBL] [Abstract][Full Text] [Related]
30. Pre-existing minor variants with NS5A L31M/V-Y93H double substitution are closely linked to virologic failure with asunaprevir plus daclatasvir treatment for genotype 1b hepatitis C virus infection.
Morishita N; Sakamori R; Yamada T; Kai Y; Tahata Y; Urabe A; Yamada R; Kodama T; Hikita H; Doi Y; Tamura S; Hagiwara H; Imai Y; Iio S; Tatsumi T; Takehara T
PLoS One; 2020; 15(6):e0234811. PubMed ID: 32544182
[TBL] [Abstract][Full Text] [Related]
31. Nonstructural protein 5A resistance profile in patients with chronic hepatitis C treated with ledipasvir-containing regimens without sofosbuvir.
Kitrinos KM; Corsa AC; Worth A; Hedskog C; Brainard DM; Miller MD; Mo H
J Viral Hepat; 2018 Feb; 25(2):126-133. PubMed ID: 28833932
[TBL] [Abstract][Full Text] [Related]
32. New resistance-associated substitutions and failure of dual oral therapy with daclatasvir and asunaprevir.
Mawatari S; Oda K; Tabu K; Ijuin S; Kumagai K; Inada Y; Uto H; Hiramine Y; Kure T; Fujisaki K; Hashiguchi M; Hori T; Oshige A; Imanaka D; Saishoji A; Taniyama O; Sakae H; Tamai T; Moriuchi A; Ido A
J Gastroenterol; 2017 Jul; 52(7):855-867. PubMed ID: 28078469
[TBL] [Abstract][Full Text] [Related]
33. Characterization of Naturally Occurring NS5A and NS5B Polymorphisms in Patients Infected with HCV Genotype 3a Treated with Direct-Acting Antiviral Agents.
Bartolini B; Giombini E; Taibi C; Lionetti R; Montalbano M; Visco-Comandini U; D'Offizi G; Capobianchi MR; McPhee F; Garbuglia AR
Viruses; 2017 Aug; 9(8):. PubMed ID: 28783119
[TBL] [Abstract][Full Text] [Related]
34. A retrospective study of the efficacy of sofosbuvir plus NS5A inhibitors for patients with hepatitis C virus genotype-2 chronic infection.
Lv DD; Wang ML; Chen EQ; Wu DB; Tao YC; Zhang DM; Tang H
Eur J Gastroenterol Hepatol; 2019 Mar; 31(3):382-388. PubMed ID: 30383554
[TBL] [Abstract][Full Text] [Related]
35. Comparison of daclatasvir resistance barriers on NS5A from hepatitis C virus genotypes 1 to 6: implications for cross-genotype activity.
Wang C; Jia L; O'Boyle DR; Sun JH; Rigat K; Valera L; Nower P; Huang X; Kienzle B; Roberts S; Gao M; Fridell RA
Antimicrob Agents Chemother; 2014 Sep; 58(9):5155-63. PubMed ID: 24936600
[TBL] [Abstract][Full Text] [Related]
36. Baseline resistance associated substitutions in HCV genotype 1 infected cohort treated with Simeprevir, Daclatasvir and Sofosbuvir in Brazil.
Aguiar BF; Campos GRF; Rodrigues JPV; Marques NN; Molina BF; Bittar C; Souza FF; Martinelli ALC; Rahal P; Pereira LRL
Clin Res Hepatol Gastroenterol; 2020 Jun; 44(3):329-339. PubMed ID: 31523019
[TBL] [Abstract][Full Text] [Related]
37. Efficacy of NS5A inhibitors against unusual and potentially difficult-to-treat HCV subtypes commonly found in sub-Saharan Africa and South East Asia.
Nguyen D; Smith D; Vaughan-Jackson A; Magri A; ; Barnes E; Simmonds P
J Hepatol; 2020 Oct; 73(4):794-799. PubMed ID: 32470499
[TBL] [Abstract][Full Text] [Related]
38. Prevalence of polymorphisms with significant resistance to NS5A inhibitors in treatment-naive patients with hepatitis C virus genotypes 1a and 3a in Sweden.
Lindström I; Kjellin M; Palanisamy N; Bondeson K; Wesslén L; Lannergard A; Lennerstrand J
Infect Dis (Lond); 2015 Aug; 47(8):555-62. PubMed ID: 25851241
[TBL] [Abstract][Full Text] [Related]
39. Real-life effectiveness and safety of the daclatasvir/asunaprevir combination therapy for genotype 1b chronic hepatitis C patients: An emphasis on the pretreatment NS5A resistance-associated substitution test.
Jang ES; Kim KA; Kim YS; Kim IH; Lee BS; Lee YJ; Chung WJ; Jeong SH
J Med Virol; 2019 Dec; 91(12):2158-2165. PubMed ID: 31452206
[TBL] [Abstract][Full Text] [Related]
40. NS5A inhibitor resistance-associated polymorphisms in Brazilian treatment-naive patients infected with genotype 1 hepatitis C virus.
Peres-da-Silva A; de Almeida AJ; Lampe E
J Antimicrob Chemother; 2015 Mar; 70(3):726-30. PubMed ID: 25414201
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
